Clinical Trial Update: Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients [Phase 1, Phase 2]

View source ↗

Summary

This document describes an ongoing Phase 1/2 clinical trial evaluating the efficacy and safety of injectable TQB2934 for systemic light-chain amyloidosis, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Light-chain Amyloidosis

Drugs mentioned

• TQB2934

Snippet

Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Conditions: Systemic Light Chain Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING